top of page

No-Exam Term Life Insurance with Arrhythmia: Why 'Irregular Heartbeat' Often Isn't Instant

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Arrhythmia can range from harmless palpitations to conditions that need ongoing treatment. Because the label covers a wide range of severity, instant underwriting tracks often require a deeper review.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

"Arrhythmia" Isn't One Diagnosis

Arrhythmia type (AFib, SVT, PVCs, etc.) and symptoms

Treatment plan (meds, ablation, cardiology follow-up)

Any related hospitalizations, syncope, or complications

The clinical category of 'arrhythmia' spans a wide range of conditions that have very different underwriting implications, and that range is exactly why instant approval tracks typically will not make a quick decision when arrhythmia appears on an application. Premature ventricular contractions (PVCs) and premature atrial contractions (PACs) are common, often benign ectopic beats that occur in structurally normal hearts - many people experience them without symptoms, they are frequently incidental findings on routine ECG, and they generally do not require treatment or significantly affect mortality risk in the absence of underlying structural heart disease. Sustained arrhythmias such as atrial fibrillation, ventricular tachycardia, and Wolff-Parkinson-White syndrome carry meaningfully different risk profiles, require active management, and are underwritten with substantially more scrutiny.

Atrial fibrillation (AFib) is the most common sustained arrhythmia and the one underwriters encounter most frequently. Whether AFib is paroxysmal (episodes that start and stop spontaneously), persistent (requires cardioversion or medication to restore normal rhythm), or permanent (normal rhythm is no longer being pursued) affects underwriting treatment because each pattern reflects a different stage of disease progression. Paroxysmal AFib in an otherwise healthy applicant who is well rate-controlled on a single medication presents very differently than longstanding persistent AFib with multiple failed cardioversion attempts - and rate-controlled persistent AFib, where the ventricular rate is managed but the fibrillation continues, occupies a distinct underwriting position because the underlying atrial substrate and long-term disease trajectory differ meaningfully from paroxysmal patterns. The classification of AFib type and the trajectory of its management over time are more informative underwriting inputs than the diagnosis label alone.

Catheter ablation as a treatment for AFib or supraventricular tachycardia (SVT) creates a specific underwriting scenario worth understanding. A successful ablation - documented by return to normal sinus rhythm with no antiarrhythmic medications, confirmed by follow-up monitoring - is viewed more favorably than ongoing rate-control therapy with persistent AFib. The ablation indicates that a definitive intervention was performed to eliminate the arrhythmic substrate, and if that intervention is durable, the applicant's ongoing risk profile may be closer to someone without arrhythmia history than someone managing a chronic condition pharmacologically. Carriers will want documentation of post-ablation monitoring - typically a 30-day event monitor or repeat Holter - confirming no recurrence before crediting the ablation as a favorable factor.

The CHADS2-VASc score is a clinical risk-stratification tool used to estimate stroke risk in AFib patients and to guide the decision about whether anticoagulation is indicated. The score assigns points for congestive heart failure, hypertension, age 75 or older, diabetes, prior stroke or TIA, vascular disease, age 65 to 74, and female sex. If an AFib applicant is on anticoagulation therapy, underwriters will look at the underlying clinical rationale - specifically what CHADS2-VASc score drove that decision - because anticoagulation for AFib indicates that the treating physician assessed the stroke risk as high enough to warrant the therapy. A higher CHADS2-VASc score embedded in an AFib application signals elevated cerebrovascular risk that carries independent underwriting significance beyond the arrhythmia itself.

The presence of an implanted loop recorder or a history of prolonged Holter monitoring is an underwriting signal that the arrhythmia was considered significant enough to warrant continuous cardiac surveillance - which is relevant even if the monitoring results ultimately came back within acceptable limits. Loop recorders are implanted subcutaneously for long-term rhythm monitoring, typically when symptomatic episodes (syncope, palpitations, pre-syncope) have not been captured on shorter monitoring. The indication for implanting a loop recorder tells the underwriter that the treating cardiologist thought the arrhythmia burden or symptom pattern warranted extended surveillance. Carriers will ask about the outcome of that monitoring but will also note the indication as part of the overall arrhythmia severity picture.

For the broader no-exam term life overview and underwriting basics, see: https://www.careproinsurance.com/instant-term-life-insurance

Education only; not to be construed as legal, tax, or medical advice. Quotes are estimates and final eligibility/pricing depend on underwriting and the issued policy language.

Frequently Asked Questions

Can I get no-exam term life insurance with arrhythmia?

Sometimes. It depends on the arrhythmia type, symptoms, treatment, and stability. Many accelerated/no-exam programs are restrictive, but other underwriting paths may exist.

Is atrial fibrillation the same as arrhythmia for underwriting?

Atrial fibrillation is one type of arrhythmia. Underwriting usually distinguishes between types, symptom severity, and treatment history. Carrier guidelines vary.

Why do no-exam programs often exclude arrhythmia?

Because "arrhythmia" covers a wide range of severity, and accelerated programs use strict filters. Many carriers prefer a deeper review to confirm stability and risk.

What arrhythmia details should I have ready?

Helpful details include arrhythmia type (if known), symptom history, meds, procedures (like ablation), cardiology follow-up, and any hospitalizations or fainting episodes.

Will I need a medical exam with arrhythmia?

Not always, but additional documentation is common. Requirements depend on the carrier, coverage amount, and specifics of your history.

What is the difference between rate control and rhythm control in AFib treatment?

Rate control manages AFib by slowing the ventricular rate with medications such as beta-blockers or calcium channel blockers, while allowing the atrial fibrillation itself to continue. Rhythm control attempts to restore and maintain normal sinus rhythm through cardioversion, antiarrhythmic medications, or ablation. Underwriters consider which strategy is being used because it reflects the treating cardiologist's assessment of disease severity and the feasibility of maintaining normal rhythm.

Does Wolff-Parkinson-White syndrome underwrite differently from AFib?

Yes. Wolff-Parkinson-White (WPW) involves an accessory electrical pathway between the atria and ventricles that can cause rapid arrhythmias. In symptomatic WPW, catheter ablation of the accessory pathway can be curative. Successfully ablated WPW with documented normal post-ablation conduction studies is underwritten more favorably than unablated WPW with symptomatic episodes, because the arrhythmic substrate has been eliminated. Asymptomatic WPW discovered incidentally is evaluated differently from symptomatic WPW that has caused tachycardia episodes.

How does a history of syncope related to arrhythmia affect underwriting?

Syncope - loss of consciousness - caused by arrhythmia is a significant underwriting flag because it indicates that the arrhythmia has produced hemodynamic compromise severe enough to cause loss of consciousness. Arrhythmia-induced syncope is evaluated differently from vasovagal syncope (the common faint), and underwriters will ask about the cause, the workup, and whether the underlying arrhythmia has been treated and documented as resolved. A history of arrhythmic syncope without a definitive treatment or clear resolution is typically a more adverse underwriting finding than a documented arrhythmia that has been treated successfully.

Get Covered With The Right Plan

Explain that "arrhythmia" can mean many things; underwriters care about type, symptoms, treatment, and stability, which is why instant tracks often won't decide quickly.

Start my term life quote

bottom of page